Member exclusive

Academy, ASRS Push Aetna to Stop Izervay Restrictions for Medicare Advantage Plans

Nov 20, 2024

Administrative Burden

Prior Authorization

The Academy and ASRS are working to minimize step therapy burdens by calling on Aetna to add Izervay to its 2025 Medicare Advantage Part B preferred drug list.

Member exclusive

Log in to keep reading.

Join AAO to get unlimited access to content. See member benefits or join today.